Jay Bradner, President, Novartis Institutes for BioMedical Research
December 14, 2021 01:54 PM EST
Cell/Gene Tx

#ASH21: The Jay Brad­ner in­ter­view: 'We're work­ing up a good­ly num­ber of deal­s'

John Carroll

Editor & Founder

John Car­roll: Well, hel­lo every­body. This is John Car­roll. I’m the ed­i­tor of End­points News, the ed­i­tor and founder of End­points News. I’m here with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times